Clinical Trial Update: Safety, Tolerability, and Immunogenicity Study of Sm-p80 + GLA-SE (SchistoShield(R)) Vaccine in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and immunogenicity of the Sm-p80 + GLA-SE SchistoShield vaccine in healthy adults; the trial is completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schistosomiasis

Drugs mentioned

• SchistoShield (Sm-p80 + GLA-SE vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Schistosomiasis | Phase 1 | Status: COMPLETED | Results posted: 2025-04-11